| Project/Area Number |
23501302
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnosis
|
|---|
| Research Institution | National Defense Medical College |
|---|
Principal Investigator |
HASE Kazuo 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究, 医学教育部医学科専門課程, 教授 (50511268)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UENO Hideki 防衛医科大学校, 病院, 講師 (90597535)
MATSUBARA Osamu 公益財団法人がん研究会, その他部局, 研究員 (40107248)
橋口 陽二郎 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究, その他部局等, 准教授 (60251253)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SHINTO Eiji 防衛医科大学校, 病院, 講師 (30626619)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | 大腸癌 / 組織マイクロアレイ / 大腸がん / 大腸癌浸潤先進部 / 簇出 / cytoplasmic podia / Stage II 大腸癌 |
|---|
| Research Abstract |
We used a tissue microarray (TMA) construction method particular about sampling areas and investigated prognostic value of various marker expressions in colorectal cancer (CRC) patients.
Using sections of 300 patients with stage II CRC, we took 4 core specimens from the submucosal invasive front, subserosal invasive front, central area and rolled edge in each tumor and constructed TMA blocks. Using these TMA sets, various marker expressions was surveyed immunohistochemically. Analyses of survival revealed that various marker expressions, such as CD133, laminin-5, mesothelin, CD44, beta-catenin, E-cadherin, SLX, showed significant prognostic values in submucosal invasive front or in subserosal invasive front. We concluded that TMA analysis disclosed the prognostic significance of various marker expressions in invasive front, and these markers seem to be promising targeted molecules for antibody therapy.
|
